Triple Therapy Shows Efficacy and Safety for Advanced Liver Cancer

Hepatocellular carcinoma (HCC), a primary liver cancer, remains a significant global health challenge, often diagnosed at advanced stages. For patients with unresectable HCC, treatment options are limited, and prognosis is generally poor. Current standard-of-care often involves targeted therapies like lenvatinib or immunotherapies such as sintilimab, but there's a critical need for more effective strategies to improve patient outcomes and survival rates. This study addresses the potential benefits of combining an immunomodulator with existing targeted and immunotherapeutic agents for unresectable HCC.

The triple combination therapy demonstrated promising efficacy in patients with unresectable HCC. The objective response rate (ORR) was 45%, with 54 patients achieving either a complete or partial response. The disease control rate (DCR), which includes stable disease, reached an impressive 80%, indicating that 96 out of 120 patients experienced disease stabilization or regression. The median progression-free survival (PFS) was 8.5 months, significantly extending the period without disease progression. The combination of thymosin alpha-1, lenvatinib, and sintilimab achieved an objective response rate of 45% in patients with unresectable hepatocellular carcinoma, demonstrating significant clinical benefit. Compared to historical data for dual therapy regimens, this triple approach showed a 15% higher ORR and a 3-month longer PFS. The overall survival (OS) was 18 months, suggesting a substantial improvement in long-term outcomes. The safety profile was manageable, with Grade 3/4 adverse events observed in 30% of patients, primarily hypertension and fatigue, which were consistent with known profiles of lenvatinib and sintilimab.